Duarte-Medrano Gilberto, Nuño-Lámbarri Natalia, Dominguez-Franco Analucia, Lopez-Rodriguez Yazmin, Minutti-Palacios Marissa, Palacios-Chavarria Adrian, La Via Luigi, Paternò Daniele Salvatore, Misseri Giovanni, Cuttone Giuseppe, Sorbello Massimiliano, Dominguez-Cherit Guillermo, Escarramán Diego
Anesthesiology Department of Medica Sur Clinic & Foundation, Mexico City, Mexico.
Anesthesiology Department of the ABC Campus Observatorio Medical Center, Mexico City, Mexico.
J Anesth Analg Crit Care. 2024 Oct 30;4(1):73. doi: 10.1186/s44158-024-00208-9.
Obesity is one of the biggest modern health issues worldwide. Owing to the failure of both behavioral and pharmacological measures, the surgical approach has been established as the main conduct to follow, with bariatric surgery being one of the most effective and safe procedures. One of the bases for the optimal analgesic strategy is the use of adjuvants during the perioperative period. One of the main drugs in use is lidocaine.
To evaluate postoperative pain after perioperative lidocaine infusion in patients undergoing bariatric surgery and describe the presence of nausea and vomiting during the first 24 h.
This was a retrospective study of patients who underwent laparoscopic bariatric surgery at ABC Medical Center. Two study arms were established: a group of patients who received lidocaine infusion and a control group. The presence of pain, nausea, or vomiting was evaluated upon admission to the recovery area and 1 h and 24 h after the intervention. The normal distribution of the data was first verified via the Shapiro-Wilk test. The data are presented as medians for quantitative variables and as frequencies for qualitative variables.
A total of 50 surgeries were performed, with a significant correlation between lidocaine infusion and lower pain values at 1 h (p = 0.04). Similarly, there was a marked trend in the presence of nausea in control group 4 (18.6%) vs. 15 (53.5%).
Our data suggest that the use of intraoperative lidocaine infusion is limited in postoperative pain management; nonetheless, it significantly improves the incidence of postoperative nausea.
肥胖是全球最大的现代健康问题之一。由于行为和药物治疗措施均告失败，手术方法已成为主要的治疗手段，减肥手术是最有效且安全的手术之一。最佳镇痛策略的基础之一是围手术期使用佐剂。目前使用的主要药物之一是利多卡因。
评估接受减肥手术患者围手术期输注利多卡因后的术后疼痛情况，并描述术后24小时内恶心和呕吐的发生情况。
这是一项对ABC医疗中心接受腹腔镜减肥手术患者的回顾性研究。设立了两个研究组：一组接受利多卡因输注的患者和一个对照组。在患者进入恢复区时以及干预后1小时和24小时评估疼痛、恶心或呕吐的情况。首先通过Shapiro-Wilk检验验证数据的正态分布。定量变量的数据以中位数表示，定性变量的数据以频率表示。
共进行了50例手术，利多卡因输注与1小时时较低的疼痛值之间存在显著相关性（p = 0.04）。同样，对照组4例（18.6%）出现恶心的明显趋势与15例（53.5%）相比。
我们的数据表明，术中输注利多卡因在术后疼痛管理中的作用有限；尽管如此，它能显著提高术后恶心的发生率。
